Grass allergy sufferers wanted for Lundbeck phase I antibody study
In a new phase I study, Lundbeck will test the safety of an antibody it acquired in 2019.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
Recruitment has been initiated for a new phase I study designed to test the safety of a once-monthly injection treatment with the antibody Lu AG09222 in patients with grass pollen allergy, according to a filing on the database Clinical Trials, which collects information about research studies.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
